---
title: Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with
  daratumumab-based frontline therapy
date: '2024-08-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39197073/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240829182955&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: We performed an international retrospective cohort study to investigate
  the prognostic impact of cytogenetic abnormalities by FISH in 283 patients with
  AL amyloidosis treated with frontline daratumumab-bortezomib-cyclophosphamide-dexamethasone
  (Dara-VCD) or Dara-VD. The cytogenetic subgroups of interest were t(11;14), gain/amp(1q)
  [hereafter, +1q], hyperdiploidy, deletion(13q), del(17p), and myeloma high-risk
  (HR) translocations (t[4;14], t[14;16], or t[14;20]). The endpoints of interest
  ...
disable_comments: true
---
We performed an international retrospective cohort study to investigate the prognostic impact of cytogenetic abnormalities by FISH in 283 patients with AL amyloidosis treated with frontline daratumumab-bortezomib-cyclophosphamide-dexamethasone (Dara-VCD) or Dara-VD. The cytogenetic subgroups of interest were t(11;14), gain/amp(1q) [hereafter, +1q], hyperdiploidy, deletion(13q), del(17p), and myeloma high-risk (HR) translocations (t[4;14], t[14;16], or t[14;20]). The endpoints of interest ...